Medical & Biological Laboratories Co., Ltd. launches real time PCR-based assay kit products for SARS-CoV-2

NAGOYA, Japan – March 23, 2020 Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announced today that its subsidiary company, G&G Science Co., Ltd., has successfully completed development of a real-time PCR assay kit for “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The kit was evaluated with clinical samples provided by the National Institute of Infectious Diseases (NIID). NIID and the Japan Ministry of Health, Labour and Welfare (MHLW) today published that the results of testing with the kit corresponded 100 percent to those of the current NIID system on both positive and negative agreement rates. Therefore, starting immediately, the kit can be used not only for emergency testing being executed under the Infectious Diseases Control Law of Japan, but also for the clinical testing for the coverage of public medical insurance.

Topics: RR & IVD

Tim Lowery Promoted to President of JSR Life Sciences, LLC

Sunnyvale, CA – June 18, 2019 – JSR Life Sciences, LLC announced today that Tim Lowery has assumed the role of president where he will oversee the Company’s global operations, which include JSR affiliate companies Crown Bioscience, KBI Biopharma, Inc., Medical & Biological Laboratories Co., LTD., Selexis SA and other affiliates throughout Europe and the Asia-Pacific region. 

Topics: Insider

Webinar: Introducing Chromassette®, a modular chromatography platform enabling next-generation bioprocess purification

Join our April 5 webinar where Ping Huang, Director, Head of DS BioProcesses, OED, Abbvie at Redwood and Masayoshi Nagaya, Sr. Global Technology Manager at JSR Life Sciences will introduce Chromassette® and an application example of an integrated rapid single pass process from harvest to purified bulk, a concept demonstrated by AbbVie.

Topics: Insider

JSR Announces the Opening of the JSR-Keio University Medical and Chemical Innovation Center

Tokyo – Nov. 21, 2017 – JSR Corporation announced today that it held the opening ceremony of the JSR-Keio University Medical and Chemical Innovation Center (JKiC) on October 28 at the Keio University Shinanomachi Campus.

Topics: Insider

Webcast on the purification of antibody fragments

On Wednesday September 13th, our colleague Gerald Platteau gave a presentation about the purification of antibody fragments with Amsphere™ A3 protein A resin. 

Topics: Insider

JSR Agrees to Acquire Medical 3D Software Company Lexi Co., Ltd.

JSR Corporation (JSR) announced that it has agreed to acquire Lexi Co., Ltd. (Lexi) a medical 3D software company. Through this acquisition, JSR will establish a new business in life sciences by integrating Lexi's 3D software technology with JSR's 3D printing and materials technologies. The JSR Group is focused on creating novel value and capitalizing on the trend toward digitization in the medical and life sciences industries.

Topics: Insider

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.

JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies

Topics: Insider

JSR Life Sciences Expands Amsphere™ A3 Production Capacity

Tokyo, Japan - May 9, 2017 – JSR Life Sciences (JLS), the global life sciences focused division of JSR Corporation, today announced plans for expansion of its production capabilities of Amsphere™ A3 protein-A chromatography resin at JSR’s Belgium subsidiary, JSR Micro NV. This expansion will effectively increase its production capacity by 6 times and provide all-important redundancy in its manufacturing capability. 

Topics: Insider

Implementation of Amsphere™ A3 in Phase II manufacturing

For several years, the JSR Life Sciences team worked closely with the LFB team at the bioproduction facility in Alès (LFB Biomanufacturing), cumulating in the implementation of the Amsphere™ A3 Protein-A media in clinical Phase II manufacturing of a monoclonal antibody. LFB recently tripled the production capacity of this facility, which also provides biomanufacturing services. The Amsphere™ A3 media offered LFB Biomanufacturing the best productivity, excellent impurity clearance and outstanding process economics in manufacturing scale.

Topics: Insider

Oncobiologics and JSR Life Sciences publish a poster on Trastuzumab purification

In a joint effort, Oncobiologics INC and JSR Life Sciences released a poster on the optimization of a Protein A Chromatography Process for a Herceptin® Biosimilar (Trastuzumab). Four Protein A resins from leading industry vendors, including AmsphereTM A3, were screened for use in the capture step for a Trastuzumab and multiple parameters were assessed for their performance against the platform resin. Please find more details in this blog or download the poster.

Topics: Insider

JSR Life Sciences Acquires Exclusive Rights to SPF Technologies’ Chromassette® Platform

JSR Life Sciences has signed a technology licensing and joint development agreement for the Chromassette® technology with SPF Technologies, LLC, a private Somerville, MA‐based company providing innovative solutions for biopharmaceutical manufacturing.

Topics: Insider

Protein A: Affinity Resin Performance Design Considerations webinar

JSR Life Sciences organized the webinar "Amsphere™ A3 Protein A: Affinity Resin Performance Design Considerations" on May 25th, 2016. Watch the replay of the entire webinar on the website of Business Review!

Topics: Insider

JSR Micro, Inc. Expands JSR Life Sciences Business with MBL International, Appoints New CEO

JSR Micro, Inc. announced today that it has expanded the JSR Life Sciences business division by becoming the majority shareholder of Boston area-based MBL International Corporation (MBLI). Tim Lowery, Sr. Vice President of Emerging Technologies at JSR Micro, Inc., has been appointed as the Chief Executive Officer of MBLI effective immediately. 

Topics: Insider

JSR Corporation Establishes JSR Life Sciences Division, Names North American Leader

The JSR Corporation announced today the formation and establishment of its Life Sciences Division, JSR Life Sciences (JLS). This newly formed JLS has been established as a business unit for Tokyo-based parent company JSR Corporation, a company with more than 50 years of success in material and polymer chemistries including marketing latex and magnetic beads to life sciences and diagnostic companies worldwide. Eric R. Johnson will lead the global operation for the Life Sciences business and assume responsibility of all operations as Senior Executive Officer of JSR Corporation and Head of the Life Sciences Division. In that capacity he will lead JLS in integrating the global operations of the US, Europe, Asia and Japan.

Topics: Insider